Recombinant Human IL17F Protein (His Tag)

Name: Recombinant Human IL17F Protein (His Tag)
Brand: Beta LifeScience
SKU: BL-0575PS
Availability: InStock

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Cytokines and growth factors, Interleukins and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	His
Host Species	Human
Synonym	Cytokine ML-1, IL-17F, Interleukin-17F precursor, IL17F, ML1, ML-1.
Background	IL-17F having an accession number of Q96PD4 is a cytokine that shares sequence similarity with IL17. IL-17F is expressed by activated T cells, and has been shown to stimulate the production of several other cytokines, including IL6, IL8, and CSF2/GM_CSF. IL-17F inhibits the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1/TGFB, and monocyte chemoattractant protein-1. IL-17F induces stromal cells to produce proinflammatory and hematopoietic cytokines. Intestinal IL17F gene expression is increased in active CD.IL-17A & IL-17F alleles influence the susceptibility to and pathophysiological features of ulcerative colitis independently. IL-17F and MIF gene polymorphisms are significantly associated with the development of functional dyspepsia.The initiation of IL-17F/IL-17R signaling pathway requires the receptor ubiquitination by TRAF6. IL-17F induces expression of IFN-gamma-inducible protein 10 (IP-10) by activating Raf1-mitogen-activated protein kinase 1/2-extracellular-regulated kinase 1/2-p90 ribosomal S6 kinase-cyclic AMP response element-binding protein signaling pathway.
Description	IL 17F His Human Recombinant expressed in E.coli is a single, non-glycosylated polypeptide chain containing 158a.a. (31-163) and having a molecular weight of 17.6kDa.IL 17F His is fused to a 25a.a. His-tag at N-terminus and purified by unique purification methods.
Source	E.coli
AA Sequence	MGSSHHHHHH SSGLVPRGSH MGSHMRKIPK VGHTFFQKPE SCPPVPGGSM KLDIGIINEN QRVSMSRNIE SRSTSPWNYT VTWDPNRYPS EVVQAQCRNL GCINAQGKED ISMNSVPIQQ ETLVVRRKHQ GCSVSFQLEK VLVTVGCTCV TPVIHHVQ
Purity	>85% as determined by SDS-PAGE.
Endotoxin	<1.0 EU per μg by the LAL method.
Formulation	The IL 17F His solution (1mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.4M Urea and 10% glycerol.
Stability	Recombinant protein is stable for 12 months at -70°C
Usage	For Research Use Only
Storage	Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.

Target Details

Target Function	Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. IL17A-IL17F is primarily involved in host defense against extracellular bacteria and fungi by inducing neutrophilic inflammation. As signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers. IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway. Via IL17RC induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Likely via IL17RC, promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression. Regulates the composition of intestinal microbiota and immune tolerance by inducing antimicrobial proteins that specifically control the growth of commensal Firmicutes and Bacteroidetes.
Subcellular Location	Secreted.
Protein Families	IL-17 family
Database References	HGNC: 16404 OMIM: 606496 KEGG: hsa:112744 STRING: 9606.ENSP00000337432 UniGene: Hs.272295
Associated Diseases	Candidiasis, familial, 6 (CANDF6)
Tissue Specificity	Expressed in T-helper 1 and T-helper 2 cells, basophils and mast cells.

Gene Functions References

the results suggest that IL17F genetic polymorphism is not associated with the development of rheumatic heart disease in South Indian population PMID: 29985710
The expression of IL-6 gene and protein was significantly induced by IL-17F. IL-17F activated TAK1 and NF-kappaB in airway smooth muscle cells. PMID: 28474507
IL-17FA7488G polymorphism was not significantly associated with colorectal cancer risk PMID: 29970680
a dietary pattern reflecting inflammation was significantly associated with colorectal cancer risk and this association could be modified according to the IL-17F rs763780 genotype and anatomic site. PMID: 29874787
Malignant T cells activate endothelial cells via IL-17 F. PMID: 28731459
The AA genotype on 7489A/G single nucleotide polymorphism of IL-17F and the A allele might be associated with a lower risk of acute rejection with better graft survival in kidney transplant recipients. PMID: 29407292
Findings suggest that IL-17F rs1889570 gene polymorphisms are significantly associated with the susceptibility to severe EV71 infection in Chinese Han children. PMID: 29549443
P-TEFb is involved in IL-17F-induced IL-8 expression and that steroids diminish it via the inhibition of CDK9 phosphorylation. PMID: 29649811
The IL-17F (+7488A/G) genotype revealed a significantly increased risk of accelerated silicosis. The IL-17F (+7488 G) allele was associated with an increased risk of accelerated silicosis. PMID: 28481151
developed ultrasensitive methods for measuring IL-17A and IL-17F in human serum samples and found that serum from psoriasis patients had higher and a broader range of concentrations of both IL-17 proteins compared to healthy volunteers PMID: 28534291
SNPs of rs3819024 in IL-17A and rs763780 in IL-17F were weakly related to a prognosis of tuberculosis. PMID: 27339100
IL17F (rs2397084) and IL10 (rs1800871) genes are associated with functional dyspepsia. PMID: 28965252
a mutation in IL-17F is associated with susceptibility to recurrent aphthous stomatitis PMID: 29458167
the G allele at rs763780 (IL-17F) was significantly associated with Takayasu Arteritis in Asian Indian population PMID: 28438554
levels of mRNA IL-17F and IL17F might be useful parameters for the diagnosis of atopic asthma patient PMID: 28606156
IL-17F rs763780 polymorphisms may be associated with the development of primary immune thrombocytopenia in a Chinese Han population. PMID: 26620416
In this study, IL-17F was demonstrated to have functions comparable to IL-17A in human keratinocytes. PMID: 27576147
Serum IL-17F predicted increased knee bone marrow lesion scores in females only among patients with knee osteoarthritis. PMID: 27836676
IL-17A and IL-17F polymorphisms therefore have the potential to act as predictive biomarkers for cervical cancer risk PMID: 28621613
The results suggest the possible involvement of the polymorphisms of IL17A G197A (rs2275913) and IL17F T7488C (rs763780) in the susceptibility to chronic Chagas disease and in development and progression of cardiomyopathy. PMID: 28470012
our study provides an inclusive meta-analysis of the function of IL-17A rs2275913 and IL-17F rs763780 genetic variations in inflammatory diseases risk. The results indicated that these two genetic variations of IL-17A and IL-17F were risk factors for inflammatory diseases, particularly RA. PMID: 28186427
This meta-analysis with seven articles in 697 patients diagnosed with chronic periodontitis , 188 patients diagnosed with aggressive periodontitis and 655 control patients totaling 1540 participants showed a non-significant association between the rs2275913 polymorphism in the IL-17A gene and the rs763780 polymorphism in the IL-17F gene with the risk of chronic periodontitis, or with aggressive periodontitis PMID: 29027636
our study provides the evidence that functional IL-23R rs1884444 G/T and IL-17F rs763780 A/G polymorphisms may be a new genetic susceptibility factor to SLE, especially in the Polish population. PMID: 27320770
IL23R rs10889677 and IL17A rs2275913 were not associated with the susceptibility to Necrotizing enterocolitis (NEC). In conclusion, data suggest that a variant of IL17F (rs763780) may contribute to the development of NEC. PMID: 28224332
Our results confirmed IL17A and IL17F as potential candidate genes involved in RA. They play pivoting roles in the susceptibility and in clinical features of RA disease. Responses to RA treatments are differently conditioned by polymorphisms in IL17A and IL17F genes. PMID: 28143790
IL17A and IL17F gene polymorphism are not the important factors associated with susceptibility and some clinical parameters of rheumatoid arthritis in a Polish population. PMID: 27169372
we aimed to investigate the associations between the 7383A/G and 7488A/G polymorphisms of the interleukin (IL)-17F gene with disease activity and clinical outcomes in Turkish patients with ankylosing spondylitis PMID: 27155445
Using an in-vitro migration assay, B cells were shown to migrate towards both IL-17A and IL-17F. These observations indicate a direct chemotactic effect of IL-17 cytokines on primary peripheral blood B cells with higher effect being on asthmatic B cells. PMID: 25494178
IL-17-related cytokines expression was amplified in bronchial/nasal mucosa of neutrophilic asthma prone to exacerbation, suggesting a pathogenic role of IL-17F in frequent exacerbators. PMID: 27931975
IL-17A (-197G/A) and IL-17F (7488T/C) SNPs were not associated with susceptibility to rheumatoid arthritis or secondary Sjogrens syndrome (sSS, p > 0.05 for both SNPs). In addition, they did not influence RA activity or clinical markers of SS. PMID: 26232893
It can be stated that the IL17A and IL17F polymorphisms are not markers of susceptibility to psoriasis. However, the IL17F polymorphism may affect the response to NB-UVB therapy. PMID: 27591988
Elevated aAbs against IL-17F correlate with disease activity in patients with early rheumatoid arthritis. PMID: 26087054
Study provides evidence that polymorphisms of both IL-17A and IL-17F may increase lung cancer risk in Chinese population. PMID: 26073462
this study shows that Korean patients with psoriasis show a strong association for IL17F single nucleotide polymorphism PMID: 27774581
we analyzed the association of three polymorphism loci (rs2275913, 197 G/A; rs3748067, 383 A/G; and rs763780, 7488 T/C) of IL-17A and IL-17F with laryngeal cancer. Allele and genotype frequencies of IL-17A rs2275913 were significantly different between patients and controls with rs2275913 (197 G/A) AA and GA+AA genotypes compared to the GG genotype significantly higher in patients. PMID: 28362993
These findings identify a novel biological function for IL-17A/F as an indirect angiogenic agent. PMID: 27594509
IL-17F was correlated with increased autoantibody levels and disease activity in primary Sjogren's syndrome and is more clinically relevant than IL-17A. PMID: 28210632
No relationship between IL17F rs763780 and rs9463772 polymorphisms and Henoch-Schonlein purpura susceptibility. PMID: 27021337
Single nucleotide polymorphisms in IL-17F A7488G but not IL-17A are associated with the development of chronic immune thrombocytopenia in China. PMID: 27312555
Study represents a comprehensive meta-analysis of the role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in cancer risk and demonstrated that these two polymorphisms significantly increase the risk of development of cancer, particularly gastric cancer. PMID: 26843459
Levels of IL-17FF were significantly higher in rheumatoid arthritis sera and showed a trend of increase in relapsing remitting multiple sclerosis, as compared with normal healthy subjects. PMID: 27620302
Polymorphism of IL-17 rs3748067 and rs763780 is closely associated with gastric cancer development. Polymorphism of L-17 rs2275913 and rs4711998 may be correlated with the risk for gastric cancer. PMID: 27097946
ELISA analysis verified high levels of Th17-associated proinflammatory cytokines such as interleukin-17A/F, interleukin-6 and interleukin-23 and low levels of inflammatory inhibitory factors including interleukin-10 and transforming growth factor-beta in primary immune thrombocytopenia patients compared with normal controls. PMID: 26484642
The GGAGAA combined genotype and the GGA haplotype of IL-17A rs2275913, IL-17F rs763780 and rs2397084 can be considered risk factors for the development of systemic lupus erythematosus in Egyptian children. PMID: 26515887
GA genotype of the rs11465553 IL17F gene polymorphism may be associated with a significantly higher risk of graft function loss and return to dialysis after kidney transplantation. PMID: 26447633
No associations were found between rs8193036, rs2275913 and rs3748067 in IL-17A and rs763780 in IL-17F SNPs and myasthenia gravis in Chinese patients PMID: 26337284
No evidence of the association was observed between rs3748067, rs3819025, rs763780, rs9382084, and rs1266828 polymorphisms and the risk of cervical cancer. PMID: 26505366
higher expression level in chronic lymphocytic leukemia patients PMID: 26478573
In vitro, CSE stimulation significantly increased IL-17F and IL-17R in 16HBE (2.5%) and A549 (5%) while IL-17A and IL-17F in PBMC (10%). IL-17A and CSE stimulation, rather than CSE or rhIL-17A alone, increased proliferation in 16HBE and apoptosis in A549 PMID: 26198032
A G/G genotype of rs766748 in IL-17F, and a C/C or C/A genotype of rs1883136 in TRAF3IP2. PMID: 26558270

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.